No title
The design and development of drugs which can permeate the blood brain barrier (BBB) for the treatment of hard-to-treat central nervous system (CNS) diseases is a critical and prevalent challenge in medicinal chemistry. Such diseases include Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) - both chronic and progressive neurodegenerative disorders affecting the brain. Galectin-3 (gal-3) is a
